The UK government has said that India's Covaxin will be added to its list of approved COVID-19 vaccines for international travellers from November 22, meaning that those inoculated with the Bharat Biotech-manufactured jab will not have to self-isolate after arrival in England.
The move follows the World Health Organisation's (WHO) Emergency Use Listing for Covaxin, which is the second most used formulation in India.
Covishield, the India-manufactured Oxford-AstraZeneca COVID-19 vaccine, was added to the UK's approved list last month.
"More good news for Indian travellers to the UK. From 22 November travellers fully vaccinated with a COVID19 vaccine recognised by WHO for Emergency Use Listing, including Covaxin, will not have to self-isolate; so joining those fully vaccinated with Covishield," Alex Ellis, British High Commissioner to India, said on Twitter on Monday.
The changes will come into effect at 4 am on November 22.
Besides Covaxin, China's Sinovac and Sinopharm, both on the WHO Emergency Use Listing, will be recognised by the UK government as approved vaccines for inbound travel, benefitting fully vaccinated people from the United Arab Emirates and Malaysia. These fully vaccinated passengers will not be required to take a pre-departure test, day-8 test or self-isolate upon arrival.
"As we continue to recover from the pandemic and expand our recognition of international vaccines, today's announcements mark the next step in our restart of international travel," said UK Transport Secretary Grant Shapps.
"The red list and quarantine system remain vital in protecting our borders and as we've said, we will not hesitate to take action by adding countries to the red list if necessary," UK Health Secretary Sajid Javid said.
The UK government has also simplified the travel rules for all under-18s coming to England. They will now be treated as fully vaccinated at the border and will be exempt from self-isolation requirements on arrival, day-8 testing and pre-departure testing. They will only be required to take one post-arrival test and a confirmatory free PCR test if they test positive.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)